Silo Pharma Initiates Human Factor Study Of SPC-15 For Treatment Of PTSD
Portfolio Pulse from Bill Haddad
Silo Pharma has initiated a human factor study of SPC-15, a drug intended for the treatment of Post-Traumatic Stress Disorder (PTSD).
October 11, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's initiation of a human factor study for SPC-15 could potentially lead to advancements in PTSD treatment, potentially impacting the company's stock positively.
The initiation of a human factor study for a new drug indicates progress in its development. If successful, this could lead to regulatory approval and potential revenue growth for Silo Pharma, positively impacting its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100